You can buy or sell EYES and other stocks, options, ETFs, and crypto commission-free!
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. Its product, the Argus II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. Read More The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
52 Week High
52 Week Low
Seeking AlphaMar 13
Second Sight Medical Products, Inc. (EYES) CEO Will McGuire on Q4 2018 Results - Earnings Call Transcript
Second Sight Medical Products, Inc. (NASDAQ:EYES) Q4 2018 Earnings Conference Call March 13, 2019 4:30 PM ET Company Participants Lisa Wilson - Investor Relations Will McGuire - President & Chief Executive Officer John Blake - Chief Financial Officer Conference Call Participants Andrew D'Silva - B. Riley Amit Dayal - H.C. Wainwright Jeb Terry - Aberdeen Investment Management Operator Ladies and gentlemen, thank you very much for standing by. And welcome to the Second Sight Q4 2018 Results Call. Du...
Stock Price, News, & Analysis for Second Sight Medical Products
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or di...
-$0.11 per share
-$0.10 per share